Estimating the decline in excess risk of chronic obstructive pulmonary disease following quitting smoking – A systematic review based on the negative exponential model  by Lee, Peter N. et al.
Regulatory Toxicology and Pharmacology 68 (2014) 231–239Contents lists available at ScienceDirect
Regulatory Toxicology and Pharmacology
journal homepage: www.elsevier .com/locate /yr tphEstimating the decline in excess risk of chronic obstructive pulmonary
disease following quitting smoking – A systematic review based on the
negative exponential model0273-2300  2013 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.yrtph.2013.12.006
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary
disease; DF, degrees of freedom; H, half-life; IARC, International Agency for
Research on Cancer; IHD, ischaemic heart disease; REF, unique reference code for
study; RR, relative risk; SE, standard error.
⇑ Corresponding author. Fax: +44 (0) 2086422135.
E-mail address: PeterLee@pnlee.co.uk (P.N. Lee).
Open access under CC BY-NC-ND license.Peter N. Lee ⇑, John S. Fry, Barbara A. Forey
P.N. Lee Statistics and Computing Ltd, Sutton, Surrey, United Kingdom
a r t i c l e i n f oArticle history:
Received 16 September 2013
Available online 19 December 2013
Keywords:
COPD
Quitting smoking
Negative exponential modela b s t r a c t
We quantiﬁed the decline in COPD risk following quitting using the negative exponential model, as pre-
viously carried out for other smoking-related diseases. We identiﬁed 14 blocks of RRs (from 11 studies)
comparing current smokers, former smokers (by time quit) and never smokers, some studies providing
sex-speciﬁc blocks. Corresponding pseudo-numbers of cases and controls/at risk formed the data for
model-ﬁtting. We estimated the half-life (H, time since quit when the excess risk becomes half that
for a continuing smoker) for each block, except for one where no decline with quitting was evident,
and H was not estimable. For the remaining 13 blocks, goodness-of-ﬁt to the model was generally ade-
quate, the combined estimate of H being 13.32 (95% CI 11.86–14.96) years. There was no heterogeneity
in H, overall or by various studied sources. Sensitivity analyses allowing for reverse causation or different
assumed times for the ﬁnal quitting period little affected the results. The model summarizes quitting data
well. The estimate of 13.32 years is substantially larger than recent estimates of 4.40 years for ischaemic
heart disease and 4.78 years for stroke, and also larger than the 9.93 years for lung cancer. Heterogeneity
was unimportant for COPD, unlike for the other three diseases.
 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license.1. Introduction
It has long been known that smoking causes chronic obstructive
pulmonary disease (COPD). In 1984, the US Surgeon General con-
cluded that, in the United States, 80–90% of morbidity from COPD
is attributable to cigarette smoking (US Surgeon General, 1984).
They noted an excess risk of COPD in former smokers, but did
not quantify how this declined by time of quit. Some authorities
subsequently made statements about this. For example, the review
‘‘The Health Beneﬁts of Smoking Cessation’’ (US Surgeon General,
1990) concluded that ‘‘Following this initial rise in COPD mortality
after cessation, the mortality ratios drop with increasing duration of
abstinence (Table 13). However, even after 20 years or more of absti-
nence, the risk of COPD mortality among former smokers remainselevated in comparison with never smokers.’’ More recently, the
International Agency for Research of Cancer (IARC) Monograph
‘‘Reversal of risk after quitting smoking’’ (International Agency for
Research on Cancer, 2007) examined the evidence in detail, noting
that ‘‘while there is a rapid improvement in terms of normalising the
rate of loss of lung function after quitting smoking, for endpoints such
as morbidity and mortality from COPD, the risk does not seem to de-
cline to the level of never smokers, even after long term cessation’’.
This review noted various methodological issues in assessing this
evidence, including reverse causation with some smokers quitting
because of disease, and difﬁculties in accurately assessing smoking
habits.
No one has previously attempted to quantify precisely the
decline in excess COPD risk following quitting, using all available
evidence and a formal model-ﬁtting procedure. As in our earlier
paper on the effects of smoking cessation on risk of ischaemic heart
disease (IHD) (Lee et al., 2012), we use the negative exponential
model to characterize the shape of the curve for each dataset by
a single parameter. This parameter, the half-life (H), is the time
since quitting when the excess risk of a quitter reaches half that
of a continuing smoker. Individual values of H can be used to assess
between-study heterogeneity, and make overall estimates. We
have also used the negative exponential model to estimate H for
lung cancer (Fry et al., 2012) and for stroke (Lee et al., 2013).
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processes: (1) airway thickening and narrowing with expiratory
airﬂow obstruction; (2) chronic mucus hypersecretion, resulting
in chronic cough and phlegm production; and (3) emphysema, an
abnormal dilation of distal airspaces combined with destruction
of alveolar walls (US Surgeon General, 1984). In our systematic re-
view of the epidemiological evidence relating smoking to these
processes we considered them separately, referring to them as
COPD, chronic bronchitis and emphysema. Here we limit attention
to COPD, as previously deﬁned (Forey et al., 2011).2. Methods
2.1. Inclusion and exclusion criteria
Attention was restricted to epidemiological prospective or case-
control studies presenting data by time of quitting smoking on
mortality or incidence of COPD. The data had to be available in a
form that allows ﬁtting of the negative exponential distribution,
as described in Section 2.5 below. Studies of effects of quitting fol-
lowing onset of COPD were excluded. As previously (Forey et al.,
2011), we limit attention to studies of the general adult population,
so do not, for example, consider studies limited to speciﬁc sets of
subjects (suffering from alpha-1 antitrypsin deﬁciency, with spe-
ciﬁc co-existing diseases, or exposed to particular respiratory
hazards).
2.2. Literature searches
An in-house database had already been created for our previous
systematic review (Forey et al., 2011). This considered papers pub-
lished up to 2007. In April 2010, a PubMed search was carried out,
restricted to the years 2006–2010, using the search terms ‘‘(COPD
or chronic bronchitis or emphysema) and (quitting smoking or
smoking cessation)’’, with abstracts inspected to identify possibly
relevant publications. Additional relevant papers were sought from
the 2007 IARC monograph on quitting (International Agency for
Research on Cancer, 2007). In August 2012 an additional PubMed
search was undertaken, using the same search terms but limited
to the years 2009–2012.
2.3. Identiﬁcation of studies
In our previous review (Forey et al., 2011), relevant papers had
been allocated to studies, each with a unique reference code (REF)
of up to 6 characters, taking into account multiple papers from the
same study, and papers reporting on multiple studies. Newly iden-
tiﬁed papers were similarly allocated, either to previously identi-
ﬁed studies, or as new studies. Care was taken to check whether
different studies involved the same groups of subjects, thus avoid-
ing double-counting in the meta-analyses. Where necessary, addi-
tional study details were obtained from other publications.
2.4. Data recorded
For each study, relevant information as previously described
(Forey et al., 2011) was entered onto a study database and a linked
relative risk (RR) database. Note that, throughout this paper, we
use the term RR to include its various estimators, including the
odds ratio and the hazard ratio. The data on the RR database relates
to sequences of RRs (‘‘blocks’’). Where possible, blocks were con-
sidered separately by sex. A block consists of a current smoker
RR and a set of former smoker RRs by period of quitting, each RR
being expressed relative to never smokers. Where originally
expressed relative to current smokers, RRs were converted to berelative to never smokers, usually by the method of Hamling
et al. (2008). The data recorded per RR were as previously de-
scribed (Forey et al., 2011).
One error in the database noticed after publication of the earlier
review (Forey et al., 2011) was corrected, the outcome being re-
categorized from CB to COPD for study ALDERS (Alderson et al.,
1985).
2.5. Statistical methods
The main features of the methods, described more fully previ-
ously (Lee et al., 2012), are summarized below.
2.5.1. Pseudo-numbers
We used the method of Hamling et al. (2008) to estimate the
pseudo-table of the numbers of cases and the numbers either in
the at risk population (for prospective studies) or of controls (for
case-control studies) that correspond to the observed RRs and
95% conﬁdence intervals (CIs). This forms the data for ﬁtting the
negative exponential distribution. Blocks with <10 estimated cases
among the former smokers were omitted from the detailed
analysis.
2.5.2. Estimated time quit
For each quitting period given in the source papers, we used the
mid-point of the lower and upper times of quitting to estimate the
time quit tj to be used in the modeling. For the ﬁnal, ‘‘open-ended
above’’, quitting group we used the mean of the lower limit and
either 50 years or the upper limit of the age range studied minus
20 years. tj is taken as inﬁnite for never smokers and zero for cur-
rent smokers.
2.5.3. Fitting the negative exponential distribution to each block
For prospective studies, the underlying model, ﬁtted to the data
by maximum likelihood methods, is Pj = A + B exp ( Ctj), where Pj
is the absolute risk of disease at time tj in group j and A, B and C are
parameters to be estimated. A is the risk in never smokers, A + B
that in current smokers, and B the increase in risk for current
smoking. H is estimated by H = (loge2)/C. Goodness-of-ﬁt to the
model was assessed from the difference in log-likelihood between
the ﬁtted and the best-ﬁt model.
For case-control studies, the model used is Fj = 1 + B exp (Ctj),
where Fj is the RR (compared to never smokers) rather than the
absolute risk. While C is interpreted as for prospective studies, B
is not, being the excess relative rather than absolute risk.
2.5.4. Regression analyses
Sources of heterogeneity were studied by inverse-variance
weighted regression of log H, between block variation in log H
being examined by study type, fatality of cases, inclusion of asth-
ma, sex, continent, publication year, mean age of subjects studied,
smoking product, current smoking RR, and numbers of cases in
quitters.
2.5.5. Sensitivity analyses
Sensitivity analyses S1 and S2 investigated the dependence of H
on possible ‘‘reverse causation’’. In S1, the group with the shortest
quitting time was omitted from each block. In S2, all groups with
an upper limit of quitting time <2 years were reallocated as current
smokers. Sensitivity analyses S3 and S4 studied the effect of using
time estimates for the ﬁnal, open-ended, quitting group based on
algorithms alternative to that described in Section 2.5.2, the value
of 50 years in that algorithm being replaced by either 30 years (S3)
or 70 years (S4).
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Data entry and most analyses were carried out using ROELEE
version 3.1 (available from P.N. Lee Statistics and Computing Ltd,
17 Cedar Road, Sutton, Surrey SM2 5DA, UK), some analyses using
excel 2003.3. Results
3.1. Searches
Initially, the database used for our review of the evidence relat-
ing smoking to COPD, chronic bronchitis and emphysema (Forey
et al., 2011) revealed nine publications with information on quit-
ting and COPD (Alderson et al., 1986; Dean et al., 1977; Forastiére
et al., 1998; Huhti and Ikkala, 1980; Jacobs et al., 1999; Kahn, 1966;
Krzyzanowski et al., 1986; Mannino et al., 2003; Rogot and Murray,
1980). The April 2010 PubMed search restricted to papers pub-
lished in 2006–2010, and inspection of the 2007 IARC Monograph
on quitting (International Agency for Research on Cancer, 2007)
identiﬁed 10 further publications as possibly relevant, (Boggia
et al., 2008; Gratziou, 2009; Jindal et al., 2006; Løkke et al., 2006;
Pelkonen et al., 2006; Pelkonen, 2008; Sai et al., 2007; Sarna
et al., 2008; Shankar et al., 2008; Streppel et al., 2007). Repeating
the search in August 2012 identiﬁed two more potentially suitable
papers (Jamrozik et al., 2011; Omori et al., 2011). Nine further pub-
lications (Buist et al., 2007; Burns et al., 1997; Dean, 1966;
Friedman et al., 1997; Kojima et al., 2007; Thorn et al., 2007; Thun
et al., 1995, 1997; Wicken, 1966) were identiﬁed from our own
in-house reference system.3.2. Studies identiﬁed
Of the 30 publications identiﬁed as possibly relevant, 19 were
rejected immediately, mainly as they only contained information
on former smokers in total, not by quitting time, or were reviews
which contained no original data. This left 11 publications
(Alderson et al., 1986; Dean et al., 1977; Forastiére et al., 1998;Table 1
Selected details of the 11 studies.
Study REFa main ref Location Sexb Study typec Start yea
ALDERS Alderson et al. (1986) UK M,F CCH 1977–82
DEAN1 Dean et al. (1977) UK M,F CCP 1969–73
FORAST Forastiére et al. (1998) USA F CCP 1993–94
FRIEDM Friedman et al. (1997) USA M,F P 1979–86
HUHTI2 Huhti and Ikkala (1980) Finland M,F CCP 1971
JACOBS Jacobs et al. (1999) Multih M P 1957–64
JAMRO1 Jamrozik et al. (2011) Australia/NZ M,F P 1996
KAHN3 Rogot and Murray (1980) USA Mi P 1954–57
KRZYZA Krzyzanowski et al. (1986) Poland M,F P(F) 1968
MANNI2 Mannino et al. (2003) USA B CS 1971–75
SHANKA Shankar et al. (2008) Singapore B P 1993–98
a Six character reference code used for study.
b M = males, F = females; M,F = results separately available for the two sexes; B = both
c CCP = case-control study with population controls, CCH = case-control study with ho
ﬁnal follow-up of a prospective study.
d Range of years when the case-control study was conducted or the baseline period f
e Only applicable to prospective studies. Relates to the longest period for which any p
f ICD = death assigned to COPD by international cause of death code; Other codes r
Physician = based on report of COPD by physician; FEV1% = based on levels of FEV1% ob
criteria. Codes for DEAN1 (ICD8 490–493) and SHANKA (ICD9 490–496) include asthma
(ICD9 491, 492, 496), FRIEDM (ICD9 491,492, 496), JAMRO1 (ICD9 491, 492, 496, ICD10
cause. FORAST excluded asthmatics.
g Abbreviations used: ALSWH = Australian Longitudinal Study on Women’s Health, H
Study, SPPARCS = Study of Physical Performance and Age-Related Changes in Sonomans
h Finland, Greece, Italy, Netherlands, Croatia and Serbia (former Yugoslavia), Japan, U
i A negligible number of women were included.
j Former smokers who quit on physicians’ orders were excluded.Friedman et al., 1997; Huhti and Ikkala, 1980; Jacobs et al., 1999;
Jamrozik et al., 2011; Krzyzanowski et al., 1986; Mannino et al.,
2003; Rogot and Murray, 1980; Shankar et al., 2008) describing
independent studies appearing to satisfy the inclusion and exclu-
sion criteria.
Table 1 gives selected details of these studies. For six of the
studies (ALDERS, FORAST, HUHTI2, JACOBS, KRZYZA and MANNI2)
the data were as entered on the original database (Forey et al.,
2011) with some additional data being added to DEAN1. Data from
the US Veterans study originally entered as studies KAHN and
KAHN2 proved unsuitable (lacking any equivalent current smoker
RR), and a new subsidiary study (KAHN3) was set up, using 16 year
follow-up data (Rogot and Murray, 1980). The remaining three
were new studies (FRIEDM, JAMRO1, SHANKA).
Of the 11 studies, four were in the USA, four in Europe, one in
Asia, one in Australasia and one involving seven countries. There
appeared to be no overlap between populations in different stud-
ies. The results relate to each sex separately in six studies, sexes
combined in two, males only in two, and females only in one. Six
were prospective studies, with follow-up periods ranging from
6.1 to 25 years, ﬁve studying mortality, and the other (KRZYZA)
carrying out spirometry on survivors at the end of follow-up. Four
were case-control studies, three using population controls and one
hospital controls, with one (DEAN1) a study of decedents, and the
other three studying the living. One was a cross-sectional study.
Four studies started in the 1950s or 1960s, four in the 1970s and
three in the 1990s. KAHN3 excluded from analysis former smokers
who quit on physicians’ orders. Two studies (DEAN1, SHANKA) in-
cluded ICD codes for asthma in their deﬁnition of outcome. Foot-
note f to Table 1 gives further details of outcome deﬁnitions.
3.3. Blocks considered in the analysis
For FRIEDM, HUHTI2 and KRZYZA, attention was limited to the
data for males, there being less than 10 quitters among the female
cases.
Table 2 gives details of the 14 blocks selected for analysis. Of the
11 studies, eight now provided only one block (ﬁve for males, oner(s)d Follow-up yearse Outcomef Commentsg
ICD (NF) Alderson hospital study
ICD Cleveland study
Physician SPPARCS study
6.1 mean 8 max ICD Kaiser Permanente study
FEV1%<60 Harjavalta study follow-up
25 ICD Seven countries study
10 ICD Females from ALSWH males from HIMS
16 ICD US Veterans–Dorn Studyj
13 FEV1%<65 Cracow study (follow-up prevalence)
GOLD NHANES I survey (baseline prevalence)
12 ICD Singapore Chinese health study
sexes – results only available for the sexes combined.
spital controls, CS = cross-sectional study, P = prospective study, P(F) = data taken at
or prospective studies.
ublication reported results.
elate to non-fatal outcome – ICD (NF) = disease (non-fatal) assigned by ICD code;
served to predicted; GOLD = Global Initiative for Chronic Obstructive Lung Disease
as an underlying cause. Codes for JACOBS (ICD8) are not given. Codes for ALDERS
J40–J44) and KAHN3 (ICD7 500–502, 527.1) do not include asthma as underlying
IMS = Health in Men Study, NHANES = National Health and Nutrition Examination
.
SA.
Table 2
Details of the 14 blocks eligible for analysisa.
Blockb Study REF Sex Age Exposurec Adjustedd Current smoker RR Cases in quitterse Quitting groups (years)f
1 ALDERS M 35–74 Cigarettes only Age 3.03 116.35 1–2, 3–9, 10+
2 F 3.45 185.10 1–2, 3–9, 10+
3 DEAN1 M 35+ Cigarettes only Age 2.78 77.58 1–4, 5–8, 9+
4 F 1.97 28.84 1–4, 5–8, 9+
5 FORAST F 55+ Cigarettes (+/ other) Age 4.66 32.08 1–10,11+
6 FRIEDM M 35+ Cigarettes only Age 10.00 12.15 2–10,11–20, 21+
7 HUHTI2 M 50–74 Any product None 36.86 12.98 1–9, 10+
8 JACOBS M 40–59 Cigarettes (+/ other) Age + 1 4.12 42.83 0.1–0.9, 1–9, 10+
9 JAMRO1 F 70–75 Any product Age + 4 21.94 68.18 0.01–5, 6–10, 11–20, 21+
10 M 65–79 21.39 98.66 0.01–5, 6–10, 11–20, 21+
11 KAHN3 M 31–84 Cigarettes (+/ other) Age 12.07 331.32 0.01–4, 5–9, 10–14,15–19, 20+
12 KRZYZA M 19–70 Cigarettes (+/ other) Age 2.84 23.93 1–8, 9–13, 14+
13 MANNI2 B 25–74 Any product Age 3.07 166.12 1–9, 10+
14 SHANKA B 45–74 Cigarettes (+/ other) Age + Sex + 5 5.00 98.43 0.01–9.99, 10+
a Where there is no entry in a column for a block, the value is that given in the next completed row above.
b Six character reference code used for study.
c ‘‘Cigarettes (+/ other)’’ = cigarettes ± other products (pipes and cigars), ‘‘Any product’’ = cigarette and/or other products.
d Age + n (or Age, sex + n) indicates the number of other non smoking risk factors that were adjusted for: JACOBS – Country cohort; JAMRO1 – Area of residence, country of
birth, level of education, marital state; SHANKA – Dialect group, years, level of education, daily ethanol intake, physical activity.
e Estimated pseudo-numbers by method of Hamling et al. (2008).
f Based on time of interview for case-control and time of baseline interview for prospective studies, except that for prospective study KAHN3 the time of quit in subjects
was re-categorized during follow-up. Thus a subject reporting having quit for 4 years at baseline, would have been counted as having quit for 9 years, 5 years later.
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sults by sex. Five blocks related to smoking of cigarettes, regardless
of pipes and cigars, ﬁve to smoking of cigarettes only, and four to
smoking of any product. The RRs were age-adjusted except for
block 7, which related to men aged 50–74 years, and adjusted for
additional non-smoking variables (see footnote d of Table 2 for de-
tails) in four blocks from three studies. Pseudo-numbers of cases in
quitters ranged from 12.15 to 331.32 (median 72.9). The 14 current
smoking RRs were heterogeneous (v2 = 198.1 on 13 degrees of
freedom (DF), p < 0.001), ranging from 1.97 to 36.86.
The number of quitting groups per block ranged from two to
ﬁve, most commonly three (seven blocks). Generally, quitting peri-
ods were as reported at time of interview in case-control studies,
or at baseline in prospective studies, with no updating of the time
as follow-up progressed. However, in KAHN3 quitting time was up-
dated at intervals based on the latest information available, with
man-years updated in the appropriate quitting period reported.
FRIEDM excluded quitters of less than two years, not apparently
reallocating them to the current smoking group.3.4. Fitting the negative exponential model to the 14 selected blocks
Fitting the negative exponential model proved to be problem-
atic for block 4 (DEAN1), where the RRs showed no decline with
increasing time quit, the RRs being 1.97 for current smokers, and
1.26, 2.64 and 1.99 for 2.5, 6.5 and 29.5 years quit respectively. In-
deed, the model best ﬁtted with a negative estimate for C suggest-
ing an increase, not a decrease, over time. As this leads to an
undeﬁned estimate for H we removed this block from our detailed
analyses, though we checked how our ﬁnal estimate ﬁtted the data
for this block.
Table 3 shows, for each block, the data used for model-ﬁtting
including the complete set of RRs and CIs (expressed relative to
never smokers), the pseudo-numbers of cases corresponding to
these RRs (‘‘cases observed’’), and the estimated values of the times
quit. Table 3 also gives, for the 13 blocks where H could be esti-
mated, the results of ﬁtting the model to each block separately,
showing the ﬁtted RR values (again relative to never smokers),
the ﬁtted numbers of cases, the estimate of H and its SE, and the
goodness-of-ﬁt chi-squared value, v2(ﬁt), together with its degrees
of freedom, DF and corresponding p value. Two Additional ﬁles givefurther information. Additional ﬁle 1: Estimates gives further de-
tails of the ﬁt, including ﬁtted values of A and B, and the full vari-
ance/covariance matrix of the estimates. Additional ﬁle 2: Plots
graphically displays the goodness-of-ﬁt for each block.
Model ﬁt is generally good, with p above 0.1 in 12 of the 13
blocks. However, in the block with most cases in quitters, KAHN3,
p was <0.001. Here, there was clear evidence of a decline in risk in
the ﬁrst few years of quitting, but risk then appeared to increase,
before declining again for longer-term quitting. However, the esti-
mate of H from this block, 13.6, is very similar to the overall esti-
mate of 13.3.
The data provide no clear evidence of reverse causation.
Observed RRs for the shortest quitting group were lower than for
current smokers in nine of the 14 blocks, the same in one, slightly
higher in three (blocks 1, 6 and 12) and only noticeably higher in
block 10. Even here, however, model ﬁt was good (p = 0.39).
Fig. 1, a forest plot, gives the ﬁtted H values and their 95% CI for
each block individually and overall. There is little evidence of het-
erogeneity between estimates of H. While the range of the esti-
mates is wide (8.8–40.2), the overall estimate of H lies within the
CI in each block, and the heterogeneity chi-squared based on in-
verse-variance weighted regression analysis of log H is estimated
at 11.12 on 12 DF (p = 0.52).
As shown in Table 4 there was no variation by any factor stud-
ied in the meta-regression analyses that was signiﬁcant at p < 0.05.
The only factor signiﬁcant at p < 0.1 was inclusion of asthma, with
H greater in those two studies in which the outcome included
those dying with asthma as the underlying cause, than it was in
other studies. There was some tendency for H to rise with increas-
ing age at baseline, as seen for IHD (Lee et al., 2012) and lung can-
cer (Fry et al., 2013) and to some extent for stroke (Lee et al., 2013),
but this was not signiﬁcant for COPD.3.5. Sensitivity analyses
Table 5 compares goodness-of-ﬁt for the main analysis and sen-
sitivity analyses S1 and S2, as described in Section 2.5.5. The over-
all ﬁt statistic for the main analysis was 17.24 on 14 DF (allowing
for observed and ﬁtted values of controls for case-control studies)
which is not signiﬁcant (p = 0.24). The ﬁt was worse for S1
(p = 0.026) and similar for S2 (p = 0.15).
Table 3
Fit of the negative exponential model to the data for the 14 blocks selected.
Block: studya Sexb Agec Smoking group Years quit RR (95% CI)d Fitted RR Cases observede Cases ﬁttedf
1: ALDERS M 35–74 Current 3.03 (1.78–5.17) 3.08 74.00 74.52
Ex 1.5 3.18 (1.71–5.93) 3.00 41.72 40.75
H = 26.97 Ex 6 2.70 (1.45–5.02) 2.78 38.16 38.68
SE(H) = 19.00 Ex 30 1.97 (1.08–3.59) 1.96 36.47 36.40
v2(ﬁt) = 0.08 (6 df) p = 1.00 Never 1.00 1.00 35.01 35.02
2: ALDERS F 35–74 Current 3.45 (2.46–4.84) 3.43 409.01 407.54
Ex 1.5 2.93 (1.90–4.52) 3.30 85.00 89.71
H = 19.04 Ex 6 3.48 (2.10–5.79) 2.95 53.90 49.97
SE(H) = 7.67 Ex 30 1.76 (1.09–2.85) 1.82 46.20 46.99
v2(ﬁt) = 1.24 (6 df) p = 0.97 Never 1.00 1.00 56.80 56.70
3: DEAN1 M 35–99 Current 2.78 (2.00–3.87) 2.75 295.26 292.61
Ex 2.5 2.27 (1.33–3.88) 2.64 23.75 26.88
H = 26.28 Ex 6.5 2.52 (1.30–4.87) 2.47 13.65 13.45
SE(H) = 13.84 Ex 29.5 1.82 (1.16–2.86) 1.80 40.18 39.87
v2(ﬁt) = 0.50 (6 df) p = 1.00 Never 1.00 1.00 45.03 45.06
4: DEAN1 F 35–99 Current 1.97 (1.42–2.72) – 80.96 78.96
Ex 2.5 1.26 (0.57–2.77) – 7.15 10.58
H = Undeﬁned Ex 6.5 2.64 (1.09–6.37) – 6.00 4.53
SE(H) = Undeﬁned Ex 29.5 1.99 (1.13–3.52) – 15.69 15.73
v2(ﬁt) = 1.89g (6 df) p = 0.93 Never 1.00 1.00 75.46 75.46
5: FORAST F 55–99 Current 4.66 (2.41–9.02) 4.99 14.39 15.06
H = 9.69 Ex 5.5 3.99 (2.16–7.34) 3.70 16.27 15.38
SE(H) = 4.18 Ex 30.5 1.41 (0.80–2.48) 1.45 15.81 16.19
v2(ﬁt) = 0.13 (5 df) p = 1.0 Never 1.00 1.00 100.19 100.04
6:FRIEDM M 35–99 Current 10.00 (3.30–30.90) 12.00 17.83 19.73
Ex 6 10.90 (2.73–43.58) 8.79 4.35 3.23
H = 12.02 Ex 15.5 7.20 (2.03–25.51) 5.50 6.79 4.78
SE(H) = 4.87 Ex 35.5 0.90 (0.10–8.05) 2.42 1.02 2.52
v2(ﬁt) = 2.47 (3 df) p = 0.48 Never 1.00 1.00 3.71 3.42
7:HUHTI2 M 50–74 Current 36.86 (2.23–608.74) 32.16 36.49 33.75
H = 16.04 Ex 5 17.00 (0.94–307.88) 26.11 6.49 9.81
SE(H) = 6.70 Ex 30 10.99 (0.61–198.22) 9.52 6.49 5.90
v2(ﬁt) = 1.79 (5 df) p = 0.88 Never 1.00 1.00 0.50 0.52
8:JACOBS M 40–59 Current 4.12 (2.61–6.51) 4.17 230.55 231.36
Ex 0.5 3.86 (1.76–8.47) 4.06 9.27 9.68
H = 10.07 Ex 5 3.43 (1.92–6.12) 3.25 27.27 25.59
SE(H) = 4.99 Ex 24.5 1.43 (0.58–3.50) 1.59 6.30 6.93
v2(ﬁt) = 0.19 (3 df) p = 0.98 Never 1.00 1.00 20.18 20.00
9:JAMRO1 F 70–75 Current 21.94 (12.68–37.96) 20.89 44.47 43.08
Ex 2.505 15.28 (8.03–29.08) 17.80 18.93 22.44
Ex 8 18.46 (9.95–34.24) 12.61 22.48 15.62
H = 10.29 Ex 15.5 5.72 (2.88–11.34) 8.00 15.11 21.51
SE(H) = 1.95 Ex 35.5 3.45 (1.65–7.23) 2.82 11.66 9.70
v2(ﬁt) = 5.96 (3 df) p = 0.11 Never 1.00 1.00 17.49 17.80
10:JAMRO2 M 65–79 Current 21.39 (8.98–50.92) 25.64 35.54 41.85
Ex 2.505 29.28 (12.00–71.41) 22.45 24.88 18.74
Ex 8 17.28 (6.86–43.52) 16.82 18.21 17.41
H = 12.51 Ex 15.5 11.36 (4.41–29.29) 11.44 15.21 15.06
SE(H) = 1.66 Ex 35.5 4.28 (1.81–10.15) 4.45 40.36 41.21
v2(ﬁt) = 3.01 (3 df) p = 0.39 Never 1.00 1.00 5.91 5.81
11:KAHN3 M 31–84 Current 12.07 (9.87–14.76) 12.69 1363.33 1397.06
Ex 2.005 11.66 (5.71–23.85) 11.56 8.01 7.74
Ex 7 14.26 (10.35–19.65) 9.19 58.11 36.50
Ex 12 10.21 (7.76–13.43) 7.35 101.23 71.06
H = 13.64 Ex 17 5.51 (4.09–7.42) 5.93 74.87 78.50
SE(H) = 0.99 Ex 35 2.43 (1.83–3.23) 2.97 89.10 106.28
v2(ﬁt) = 26.40 (3 df) p < 0.001 Never 1.00 1.00 101.76 99.19
12:KRZYZA M 19–70 Current 2.84 (1.15–7.01) 2.97 40.29 41.99
Ex 4.5 3.38 (1.21–9,41) 2.82 12.64 10.52
H = 40.17 Ex 11 2.57(0.70–9.41) 2.63 4.29 4.37
SE(H) = 50.01 Ex 32 2.03 (0.65–6.35) 2.13 7.01 7.35
v2(ﬁt) = 0.54 (3 df) p = 0.91 Never 1.00 1.00 5.58 5.57
13:MANNI2 M + F 25–74 Current 3.07 (2.58–3.65) 3.04 646.97 644.72
H = 8.83 Ex 5 2.32 (1.82–2.97) 2.38 122.62 125.76
SE(H) = 3.18 Ex 30 1.26 (0.89–1.78) 1.19 43.50 41.63
v2(ﬁt) = 0.20 (5 df) p = 1.00 Never 1.00 1.00 183.49 184.48
14:SHANKA M + F 45–74 Current 5.00 (3.73–6.71) 5.25 82.93 87.00
(continued on next page)
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Table 3 (continued)
Block: studya Sexb Agec Smoking group Years quit RR (95% CI)d Fitted RR Cases observede Cases ﬁttedf
H = 21.01 Ex 5 5.00 (3.64–6.87) 4.60 63.22 58.16
SE(H) = 6.36 Ex 30 2.50 (1.70–3.68) 2.58 35.21 36.30
v2(ﬁt) = 0.66 (3 df) p = 0.88 Never 1.00 1.00 98.42 98.32
a For each block, the block number and study reference code is shown. Also shown in this column is the estimate of half-life, H, its standard error, SE(H), and the chi-squared
value for ﬁt of the model, v2(ﬁt), based on twice the difference in log-likelihood between the ﬁtted model and the best-ﬁt model.
b Apart from the sex of the subjects considered in the block, the entries in the column also show the DF for v2(ﬁt).
c Apart from the age group of the subjects considered in the block, the entries in the column also show the probability (p) value associated with v2(ﬁt) and its DF.
d The source of these data is as follows: Blocks 9,10, RRs and CIs as given; Blocks 1,2,3,4,6,11, RRs by years quit given, with CIs estimated from numbers and person-years;
Blocks 5,14, RRs and CIs recalculated by combining levels; Block 7, RRs and CIs recalculated using 0.5 for zero cells; Block 8, RRs and CIs calculated from numbers at risk and
age- and cohort-adjusted rates; Block 12, RRs and CIs calculated from age adjusted rate and number at risk; Block 13, RRs and CIs calculated from age adjusted % summed over
disease groups.
e Estimated pseudo-numbers of cases (Hamling et al., 2008). Corresponding values for the controls and at risk population are available on request. Fitted values of the other
parameters A and B are given in Additional ﬁle 1.
f Corresponding values for the controls are available on request.
g Based on a ﬁtted model with the RR assumed to be the same in each group of former smokers as in the current smokers.
Fig. 1. Forest plot of half-life estimates. Table 4 presents results of inverse-variance weighted analysis of log H based on 13 blocks, with the estimates converted back to the
original scale by taking exponentials. The individual study estimates and the 95% CI are shown in the ﬁgure, both numerically and graphically, on a logarithmic scale. In the
graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log H). Arrows indicate
where the CI extends outside the range indicated. Also shown is the combined estimate, based on inverse-variance weighted analysis of log H. This is represented by a
diamond of standard height, with the width indicating the 95% CI.
236 P.N. Lee et al. / Regulatory Toxicology and Pharmacology 68 (2014) 231–239Table 6 compares ﬁtted H values and goodness-of-ﬁt for the
main analysis, and for all four sensitivity analyses, S1 and S2 test-
ing for dependence of H on possible ‘‘reverse causation’’, and S3
and S4 studying the effect of using alternative time estimates
for the ﬁnal group (see Section 2.5.5). Estimates of H varied little
between the main analysis and analyses S1 or S2. In S3 the time
estimate was reduced in all 13 blocks, while in S4 it was in-
creased in eleven blocks and unchanged in two. This led to de-
creased estimates of H in S3 with an overall estimate of
10.42 years, 21.8% less than for the main analysis (13.32 years).
Similarly estimates of H increased in S4 with an overall estimate
of 14.90 years, 11.9% more than for the main analysis. The only
evidence of misﬁt was for KAHN3, which was signiﬁcant across
all analyses.
We also ﬁtted our main analysis estimate of H (13.32) to the
data in all 14 blocks. Only block 11 showed a signiﬁcant misﬁt,
the ﬁt for the rejected block 4 being 4.95 on 5 DF (p = 0.42). The
ﬁt chi-squared for block 11 was very similar using this overall esti-
mate of H (26.50 on 2 DF) and using the estimate based only on the
data for that block (26.40).4. Discussion
As noted earlier (Lee et al., 2012) when reporting on quitting
and IHD, the negative exponential model has many attractions,
including its simple functional form, easily understood interpreta-
tion, and possible application to data for various smoking-related
diseases and to studying effects of switching to a reduced daily
consumption, or a reduced exposure product. That paper includes
extensive discussion of various problems affecting the reliability
of the derived estimates of H, including the accuracy of recorded
smoking habits, the fact that some studies report quit time as re-
corded at baseline while others update it from repeat interviews
or with increasing length of follow-up, the effects of reverse causa-
tion, difﬁculties in estimating midpoints of time intervals, the use
of pseudo-numbers, and the fact that the method used cannot in-
clude RRs adjusted for other smoking variables. We do not intend
to discuss these issues further here, preferring to emphasise the
main problems speciﬁc to COPD and the conclusions to be drawn.
The main problem with the COPD data relates to the limited
number of blocks, 14, which is similar to the 11 for stroke (Lee
Table 5
Observed and ﬁtted COPD cases by time quit smoking for the main analysis and sensitivity analyses S1 and S2.
Time of quitting smoking Main analysis Sensitivity S1a Sensitivity S2b
Observedc Fittedd Observedc Fittedd Observedc Fittedd
Current smokers 3291.05 3330.28 3291.05 3332.59 3427.04 3470.27
<2 135.99 140.13 – – – –
2 to < 5 88.21 86.32 – – 88.21 86.32
5 to < 10 444.73 409.56 231.78 196.84 444.73 409.41
10 to < 15 105.52 75.43 105.52 75.24 105.52 75.43
15 to < 20 111.98 119.85 111.98 119.28 111.98 119.85
20+ 379.29 397.26 379.29 398.51 379.29 397.59
Never smokers 674.08 671.92 674.08 671.14 674.08 671.87
Total 5230.85 5230.75 4793.70 4793.61 5230.85 5230.75
Fit statistice 17.24 (df = 14, p = 0.24) 20.38 (df = 10, p = 0.026) 17.09 (df = 12, p = 0.15)
a Omitting the estimate in each block with the shortest quitting period.
b Counting estimates with an upper limit of quitting time of 2 years as applying to current smokers.
c Observed pseudo-number of COPD cases, summed over blocks.
d Fitted pseudo-number of COPD cases, summed over blocks. For each block, the ﬁtted number of cases is calculated from the numbers at risk and the ﬁtted relative risks by
years quit.
e Based on summation of (observed-ﬁtted)2/ﬁtted, the summation also including terms for the observed and ﬁtted total number of controls (not shown). The statistic can be
considered approximately chi-squared distributed.
Table 4
Estimatesa of H by various block characteristics.
Characteristic Level Nb pc H (95% CI)
All All 13 – 13.32 (11.86–14.96)
Study type Case-control 6 0.67 14.34 (9.66–21.30)
Prospective 7 13.22 (11.63–15.01)
Fatality of cases Fatal 7 0.92 13.29 (11.70–15.11)
Non-fatal 6 13.58 (8.93–20.66)
Inclusion of asthma Included 2 0.06 22.21 (13.91–35.46)
Not as underlying cause 9 13.12 (11.84–14.53)
Otherd 2 9.85 (5.52–17.59)
Sex Male 8 0.51 14.67 (8.82–24.40)
Female 3 13.56 (11.86–15.51)
Combined 2 11.24 (7.92–15.94)
Continent N America 4 0.12 13.26 (11.63–15.11)
Europe 5 20.47 (13.15–31.88)
Other 4 12.43 (10.28–15.03)
Publication year Before 1990 6 0.15 14.14 (12.31–16.24)
From 1990 7 12.00 (9.99–14.41)
Age at baseline <50 3 0.22 9.97 (5.67–17.55)
50–59 4 14.18 (12.35–16.28)
60–69 3 16.06 (9.70–26.60)
70+ 3 11.60 (9.40–14.31)
Smoking product Any producte 4 0.14 11.69 (9.62–14.21)
Cigarettesf 5 13.79 (12.07–15.75)
Cigarettes only 4 18.06 (11.43–28.54)
Current smoker RR 2.00–2.99 2 0.29 28.03 (10.23–76.83)
3.00–3.99 3 13.70 (8.13–23.08)
>=4.00 8 13.16 (11.69–14.82)
Cases in quitters <100 9 0.58 12.78 (10.36–15.77)
100+ 4 13.64 (11.72–15.88)
a Based on inverse-variance weighted analysis of log H, with the estimates converted back to the original scale by taking exponentials.
b Number of blocks.
c Probability value for difference between groups.
d Includes FORAST where asthmatics were excluded and JACOBS where inclusion of asthma was not stated.
e ‘‘Any product’’ = cigarettes, pipes and/or cigars.
f Cigarettes’’ = cigarettes regardless of other products (pipes and cigars).
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the 106 for lung cancer (Fry et al., 2012). However, since the under-
lying effect size is quite large, a fairly stable overall estimate of H
could still be obtained. In the analysis of stroke (submitted for pub-
lication) nine of 22 (41%) current smoker RRs were <1.40, whereas
here all RRs were >1.97.
We rejected one block of data from our meta-analyses as it
could not be successfully be ﬁtted to the negative exponential.
However, the results from the other blocks were homogeneous,
the heterogeneity chi-squared being 11.12 on 12 DF (p = 0.52).Furthermore the estimate of H derived from the 13 blocks did ﬁt
the data from the rejected block.
There was some evidence of variation in H (p = 0.06) by consid-
eration of asthma in the outcome deﬁnition. In most studies, the
deﬁnition of COPD excluded cases where asthma was the underly-
ing diagnosis but included cases of chronic bronchitis or emphy-
sema where asthma was also present. However estimates of H
were higher in the two studies where the deﬁnition included asth-
ma as the underlying diagnosis. More evidence is clearly needed
before any ﬁrm conclusions can be drawn. We limited analysis to
Table 6
Comparison of ﬁtted H values and goodness-of-ﬁt for the main and sensitivity analyses.a
Blockb Main analysisc Sensitivity analysis S1d Sensitivity analysis S2e Sensitivity analysis S3f Sensitivity analysis S4g
1 26.97 28.24 27.15 18.02 28.81
2 19.04 18.81 19.78 13.47 20.18
3 26.28 26.42 26.28 17.46 35.33
5 9.69 9.66 9.69 6.75 12.78
6 12.02 11.81 12.02 10.57 13.50
7 16.04 16.27 16.04 10.28 17.23
8 10.07 10.06 10.11 8.95 10.07
9 10.29 9.96 10.29 8.39 10.78
10 12.51 13.31 12.51 9.24 14.06
11 13.64⁄⁄⁄ 13.64⁄⁄⁄ 13.64⁄⁄⁄ 11.20⁄⁄⁄ 15.39⁄⁄⁄
12 40.17 38.81 40.17 31.04 40.17
13 8.83 10.02 8.83 7.15 9.12
14 21.01 21.20 21.01 14.55 22.34
Totalh 13.32 13.47 13.33 10.42 14.90
a The values shown in the table are the ﬁtted H values. Where there is evidence of misﬁt, this is indicated by: ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
b See Table 3 for details of the blocks.
c Results as shown also in Table 3.
d Omitting the group in each block with the lowest quitting period.
e Combining groups with an upper limit of quitting time up to 2 years with the current smokers. Indicates where this estimate is the same as for the main analysis.
f Using alternative estimate of time quit for the ﬁnal, open-ended, period of quitting, estimated as the mean of the lower limit and either 30 years or the upper limit of the
age range studied minus 30 years, if this is smaller than 30 years.
g Using alternative estimate of time quit for the ﬁnal, open-ended, period of quitting, estimated as the mean of the lower limit and either 70 years or the upper limit of the
age range studied minus 70 years, if this is smaller than 70 years. Indicates where this estimate is the same as for the main analysis.
h The inverse-variance weighted mean of log H, converted back to the original scale.
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suitable results for chronic bronchitis and particularly for emphy-
sema were so limited. We therefore cannot draw any conclusions
as to whether effects of quitting smoking vary for the different dis-
ease processes that COPD comprises.
Sensitivity analyses showed that allowing for reverse causation
did not materially affect the estimates of H. This was true also for
study KAHN3, where smokers quitting on physicians’ orders had
been excluded from analysis. However, varying the estimates of
time quit used for open ended ranges did move the estimate of H
up or down to some extent.
The overall estimate of H of 13.32 (95% CI 11.86–14.96) years is
substantially larger than estimated for IHD of 4.40 (3.26–5.95) (Lee
et al., 2012), or for stroke of 4.78 (2.17–10.50) (Lee et al., 2013) and
is even higher than that estimated for lung cancer of 9.93 (9.31–
10.60) (Fry et al., 2012). Our ﬁndings align with the impression gi-
ven by the US Surgeon General that after 20 years of quitting, COPD
risk still remains elevated in comparison with never smokers (US
Surgeon General, 1990), as our estimate of 13.32 for H implies that
35.3% of the excess risk would still exist after 20 years.5. Conclusions
Though the data on quitting smoking and COPD are quite lim-
ited, they ﬁt the negative exponential model. The results add fur-
ther support to the idea that, for a number of smoking-related
diseases, the decline in excess risk following quitting can be
approximated using the model, though the half-life varies by dis-
ease, being clearly longer for lung cancer and COPD than for IHD
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